Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-004232-22-DK

Enrollment

Unknown

Registered

2007-10-17

Start date

2009-03-24

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients resistant to treatment of colorectal cancer MedDRA version: 9.1 Level: LLT Classification code 10061451 Term: Colorectal cancer

Interventions

Trade Name: SUTENT Product Name: Sutent Pharmaceutical Form: Capsule, hard Trade Name: CAMPTO Product Name: Irinotecan Product Code: A596 Pharmaceutical Form: Intravenous infusion Trade Name: Erbitu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026